Thank you to everyone who registered for our upcoming symposium. We are thrilled to see such a strong interest in our event.
Our team is currently processing all registrations, and we will soon be reaching out to confirm your attendance. Keep an eye on your email, as we'll be sending out confirmation details and additional event information shortly.
Stay tuned for more updates, and in the meantime, feel free to contact us if you have any questions at: nataliaczerniak@vhio.net
Information
Organizers
Dr Alena Gros (VHIO, Barcelona) | Dr Sonia Guedan (IDIBAPS, Barcelona)
Topics | Sessions
• Determinants of ACT activity
• Adoptive cell therapies for solid cancers • Next-generation CAR T- cells
• Adoptive cell therapies for solid cancers • Next-generation CAR T- cells
• Adoptive cell therapies for pediatric indications
• Advances in CAR T- cells for hematological malignancies
• Advancing T-cell therapies for solid cancers
Speakers
• Dr Dirk Busch
Munich, Germany
• Dr Luca Gattinoni
Regensburg, Germany
• Dr John Haanen
Amsterdam, The Netherlands
• Dr Chris Klebanof
New York, USA
• Dr Robbie Majzner
Stanford, California
• Dr Silvia Martin Lluesma
Barcelona, Spain
• Dr Víctor Moreno García
Madrid, Spain
• Dr Antonio Pérez Martínez
Madrid, Spain
• Dr Concetta Quintarelli
Rome, Italy
• Dr Andy Sewell
Cardiff, UK
• Dr Melody Smith
Stanford, California
• Dr Álvaro Urbano
Barcelona, Spain
• Dr Claire Roddie
London, UK
The Vall d’Hebron Institute of Oncology (VHIO), a reference center for personalized medicine in oncology, was created in 2006. Thanks to its pioneering multidisciplinary and translational research model and its participation in consortia and projects with other prestigious centers worldwide, it has positioned itself as one of Europe's most important comprehensive centers. VHIO is capable of transforming, in record time, the latest research discoveries in the laboratory in early clinical trials and, therefore, in new opportunities for cancer patients, including cell therapies.
The BBVA Foundation promotes knowledge through research, artistic endeavors, and cultural creations. In collaboration with VHIO, the Foundation established the pioneering Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI) in 2017. This program has significantly improved VHIO's research in Immuno-Oncology, as well as advanced the development of cell therapies. As a result of this valuable support, we are delighted to present the inaugural symposium, which aims to disseminate high-quality research findings and foster collaboration among international experts to advance our understanding of cancer.
